Torque, an immuno-oncology company developing Deep Primed cell therapies that direct and evoke immune responses in the tumor microenvironment, announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering.

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series.

Nemera received from the German Government Drug Administration (Government Presidium, Tübingen) the Pharmaceutical Drug Manufacturing Authorization according to §13 AMG (German Drug & Medicinal Product Law) at its Neuenburg manufacturing facility in Germany.

Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel). 

Elsevier, the information analytics business specializing in science and health, has announced it is donating its Unified Data Model (UDM) to The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D.

Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.